RETIRED - Correct Coding - Oral Anticancer Drugs and PDAC's NDC/HCPCS Crosswalk Listings

IMPORTANT: THIS DOCUMENT CONTAINS OUTDATED INFORMATION.Content Provided on this page contains outdated information and instruction and should not be considered current. Noridian is providing this archived information for research purposes only. This archived article contains previously issued instructions that have since been updated or are no longer applicable for Medicare billing purposes.

Article retired due to content incorporation into the applicable Local Coverage Determination or related Policy Article.

Joint DME MAC Publication

Occasionally pharmaceutical manufacturers release drugs with NDCs and they do not immediately appear on the NDC/HCPCS crosswalk list maintained by the Pricing, Data Analysis and Coding (PDAC) contractor (see article from April 2013 entitled "Oral Anticancer Drugs – Coding and Billing Change").  This recently happened when Roxane Laboratories, Inc., a manufacturer of oral cyclophosphamide, discontinued their tablet forms of the drug and substituted capsules.  Initially the capsule forms of the drug (NDC 00054-0382-25 for the 25 mg strength and NDC 00054-0383-25 for the 50 mg strength) were not on the NDC/HCPCS crosswalk list.  This list has now been updated to reflect the new dosage forms and NDC numbers for Roxane's cyclophosphamide.    

If a supplier bills an oral anticancer drug with an NDC number that is not on the NDC/HCPCS crosswalk list, the claim will receive a front-end reject by CEDI.  To avoid this situation, suppliers should follow the instructions in the Coding Guidelines section of the Oral Anticancer Drugs related Policy Article (PA) which states:

A list of valid NDC numbers called the "NDC/HCPCS Crosswalk" for covered oral anticancer drugs can be found on the Pricing, Data Analysis and Coding (PDAC) Contractor web site. Until a new NDC number is added to the list, suppliers must submit claims using code J8999.

Until a new NDC number is added to the list in the monthly update, suppliers have two options:

  1. Hold claim submission until the NDC/HCPCS Crosswalk reflects the monthly update of covered OACDs; or,
  2. Submit claims using code J8999.

Claims submitted using code J8999 must include the name of the drug, the manufacturer, the NDC number, the dosage strength of each drug form (e.g., capsule, tablet, suppository, liquid) and the number of tablets or capsules dispensed. This information must be entered in the narrative field of an electronic claim (NTE 2300 or NTE 2400 of an electronic claim) or Item 19 of a paper claim.

The NDC/HCPCS Crosswalk files can be found on the PDAC Web site at https://www.dmepdac.com/crosswalk/index.html

 

Last Updated Thu, 10 Jan 2019 13:05:10 +0000